VIR BIOTECHNOLOGY INC (VIR)
Health Care · Clinical-stage immunology and virology therapeutics · NASDAQ
Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking technologies.
What VIR BIOTECHNOLOGY INC does
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat and prevent serious infectious diseases and cancer. The company leverages its proprietary immunology and virology platforms, including masking and targeted T-cell engagement technologies, to advance product candidates across its pipeline. Vir's programs span hepatitis delta virus, masked T-cell engager therapies, and other infectious disease and oncology indications.
Themes: ["Infectious disease / virology","Immunology and T-cell therapy","Hepatitis delta virus (HDV)","Cancer immunotherapy","Masked therapeutics"]
Fundamentals
- Price$10.34 as of 2026-07-09 close
- Market cap$1.7B as of 2026-07-10
- 1-year return+96.8% as of 2026-07-09 close
- Net margin-638.9% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE-49.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-7.6% as of 2026-07-10
- Revenue CAGR (3y)-65.1% SEC XBRL
- Beta1.60 as of 2026-07-10
Key risks (from latest filing)
["Drug development and commercialization carry substantial risks with only a small number of R&D programs achieving commercialization; early-stage clinical results may not predict later-stage or larger-scale study outcomes and do not ensure regulatory approval.","Rapid changes and intense competition in the biopharmaceutical environment create ongoing business risks and uncertainties.","The company is unprofitable with a net margin of -638.87% and declining revenue, creating ongoing financing and cash burn risks."]
Competitors & peers
- Gilead Sciences
- Regeneron Pharmaceuticals
- Moderna
- BioNTech
- Juno Therapeutics (Celgene)
- Merck
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.